Galapagos SA

Gilead Sciences committed billions of dollars to Galapagos in an autoimmune disease partnership that has fallen well short of expectations. But the drugmaker isn’t giving up on this therapeutic area and it is now striking up a new alliance with a new partner whose technology could yield therapies for rheumatoid arthritis and lupus. The partner is EVOQ Therapeutics, a startup whose technology takes a novel approach to preventing an immune response to a particular antigen. Specific financial terms of the deal announced Tuesday were not disclosed, but the companies said EVOQ could receive up to $685.5 million in upfront, option exercise, and milestone payments. Autoimmune diseases develop when the balance of the immune system is tipped toward excessive activation of immune cells. EVOQ’s approach to treating such diseases involves targeting dendritic cells, antigen-presenting cells that prime immune cells toward a response of immune tolerance or immune activation. The company says its technology can stimulate dendritic cells toward an anti-inflammatory response that restores immune tolerance, a state in which the immune system recognizes the antigens of the body and does not attack them. The EVOQ technology, called NanoDisc, is designed to enable delivery of disease-specific antigens to the lymph nodes, which are depositories of large numbers of dendritic cells. According to the terms of the agreement with Gilead, both companies will collaborate on preclinical research. The deal gives Gilead the option to exclusively license rights to the NanoDisc technology for rheumatoid arthritis and lupus. If the Foster City, California-based drugmaker exercises those options, it will be responsible for clinical development of drug candidates. If the drugs secure regulatory approval, Gilead will also handle their commercialization. EVOQ would then receive royalties from Gilead’s sales of commercialized products. “Despite key advances over the past two decades, there remains significant unmet need for people living with inflammatory and autoimmune diseases,” Flavius Martin, Gilead’s executive vice president, research, said in a prepared statement. “We are excited to collaborate with EVOQ to further expand our autoimmune pipeline with the goal of addressing the needs of people living with these conditions.” Gilead expressed similar sentiments in 2019, when it inked a $5 billion deal to collaborate with Galapagos on six clinical-stage drugs and 20 more in preclinical development. That deal expanded on an earlier alliance on filgotinib, which was rejected by the FDA but went on to receive regulatory approvals in Japan and Europe for treating rheumatoid arthritis. That drug is now largely in the hands of Galapagos, though Gilead will collect royalties from its partner’s sales of the product. Other partnered programs have also had setbacks. In 2021, Gilead and Galapagos stopped development of ziritaxestat in ideopathic pulmonary fibrosis after an independent data monitoring committee evaluated clinical data and concluded the drug’s benefits do not outweigh its risks. Gilead is EVOQ’s second big pharma partner. Two years ago, the startup unveiled a license and collaboration agreement with Amgen covering the development of new drugs for autoimmune disorders that were not disclosed. That deal puts EVOQ in line for up to $240 million in upfront and milestone payments.

Mechelen, Belgium; 23 December 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 22 December 2022 from FMR LLC, who notified that it holds 3,884,633 of Galapagos’ voting rights, consisting of 3,884,633 ordinary shares. FMR LLC controls investment funds Fidelity Management & Research Company LLC, FIAM Holdings LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,367,506 voting rights, Fidelity Management Trust Company increased its position to 500,070 voting rights and Strategic Advisers LLC decreased its position to 510 voting rights. Hence, the first-mentioned controlled undertaking of the FMR LLC group individually crossed above the 5% threshold. FMR LLC's holding of 3,884,633 Galapagos' voting rights, including its controlled undertakings’ holdings, represents 5.90% of Galapagos' currently outstanding 65,835,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos’ voting rights. The full transparency notice is available on the Galapagos website. About GalapagosGalapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter. ContactInvestors:Sofie Van GijselHead of Investor Relations+1 781 296 1143 Sandra CauwenberghsDirector Investor Relations+32 495 58 46 63ir@glpg.com Media:Marieke VermeerschHead of Corporate Communication+32 479 490 603media@glpg.com 1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market Attachment Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee effective 1 January 2023. Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Officer and member of the Executive Committee. Dr. Paul Stoffels1, CEO and Chairman of Galapagos said: “On behalf of the Board, I want to thank Walid and André for their commitment and contributions throughout the years. Walid joined the company in early 2017 and led it through a critical and transformative phase, including the successful completion of the Phase 3 studies of filgotinib in rheumatoid arthritis and ulcerative colitis. We recognize his important contribution to building out the development organization and to bringing our company to the fully integrated biotech that we are today. Since joining Galapagos as a pre-IPO company in 2005, André has led the business development function and played an important role in the company’s growth through a large series of pharma partnerships, including the Gilead collaboration.” The company anticipates announcing a Head of R&D and Executive Committee member in the first half of 2023. Until such appointment, Dr. Paul Stoffels1 will act as Head of R&D ad interim. Additionally, the company’s senior leadership team has been strengthened with key hires and internal promotions in Research, Development, Business Development and Commercial. Furthermore, the Board of Directors of Galapagos appointed two new members to the Executive Committee: Ms. Annelies Missotten, Chief Human Resources Officer Annelies joined Galapagos early 2018 from GSK, where she was HR Business Leader of Global Vaccines Commercial & Global Vaccines Strategic Partnerships Ms. Valeria Cnossen, General Counsel, also responsible for Compliance & Ethics, the Corporate Secretary Office and Intellectual Property Valeria joined Galapagos in August 2022. She previously was General Counsel of the Consumer Health Group of Johnson & Johnson and held leadership roles in the Pharmaceuticals Group and Medical Devices Group of Johnson & Johnson “I am very pleased that our Executive Committee is strengthened with key strategic positions to help drive future growth. Annelies and Valeria bring a wealth of expertise and will be instrumental in setting and executing on our human capital strategy and our corporate governance,” commented Dr. Paul Stoffels, CEO and Chairman of Galapagos. About GalapagosGalapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter. Except for filgotinib’s approval for the treatment of moderately to severely rheumatoid arthritis and ulcerative colitis by the relevant regulatory authorities in the European Union, Great Britain, and Japan, our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority. ContactInvestors:Sofie Van GijselHead of Investor Relations+1 781 296 1143 Sandra CauwenberghsDirector Investor Relations+32 495 58 46 63ir@glpg.com Media:Marieke VermeerschHead of Corporate Communication+32 479 490 603media@glpg.com Forward-looking statementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the announced leadership transition and Executive Committee appointments, benefits the company expects to realize from new additions to its Executive Committee, its ability to accelerate its development activities and its strategic direction model, and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “vision,” “aims”, and “plans,” or words of similar meaning. These forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that we may not be able to realize the expected benefits from our planned leadership transition, that our leadership transition may be disruptive to our business operations, and those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2021 and our subsequent filings with the SEC. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations. 1 Acting via Stoffels IMC BV Attachment Galapagos announces changes to Executive Committee